Skip to main content
Erschienen in: Indian Journal of Hematology and Blood Transfusion 2/2017

25.08.2016 | Correspondence

Autologous Blood Transfusion as a Life Saving Measure for a Trauma Patient with Fracture Femur and Drug Induced Hemolytic Anemia: A Case Report

verfasst von: Sumit Vishwakarma, Rahul Chaurasia, Arulselvi Subramanian, Vivek Trikha, Kabita Chatterjee

Erschienen in: Indian Journal of Hematology and Blood Transfusion | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

A positive direct antiglobulin test has been reported in 1:1000 to 1:14,000 blood donors and 1–15 % of hospital patients. Drugs may cause a positive direct antiglobulin test result and/or immune-mediated haemolysis with an incidence of approximately 1 in a 1 million population. Our aim is to highlight the importance of following strict transfusion protocols and management insight in a direct antiglobulin test positive patient showing incompatibility with multiple units possibly due to drug induced immune haemolytic anaemia (DIIHA). We also aim to highlight importance of autologous blood transfusion in an orthopaedic procedure in which homologous transfusion may be needed. We are presenting case of a 36 year old male with alleged h/o of road traffic accident with comminuted intra-articular fracture of the distal femur. He had h/o of ankylosing spondylitis since last 20 years on medication with indomethacin and methotrexate. A review of the literature was performed which showed use of drug methotrexate as an uncommon clinical entity for DIIHA; sporadic reports exist in the medical literature to support this view. The review of the literature in combination with our own data showed methotrexate can be a cause of DIIHA. We therefore advocate proper immunohaematological work up and use of autologous blood for management of at-risk-patients of DIIHA.
Literatur
1.
Zurück zum Zitat Petz LD, Garratty G (2004) Immune haemolytic anaemia’s, 2nd edn. Churchill Livingstone, Philadelphia, p 261e317 Petz LD, Garratty G (2004) Immune haemolytic anaemia’s, 2nd edn. Churchill Livingstone, Philadelphia, p 261e317
2.
Zurück zum Zitat Snapper I, Marks D, Schwartz L, Hollander L (1953) Hemolytic anemia secondary to mesantoin. Ann Intern Med 39:619–623CrossRefPubMed Snapper I, Marks D, Schwartz L, Hollander L (1953) Hemolytic anemia secondary to mesantoin. Ann Intern Med 39:619–623CrossRefPubMed
4.
Zurück zum Zitat Garratty G, Arndt PA (2007) An update on drug-induced immune haemolytic anemia. Immunohematology 23:105–119PubMed Garratty G, Arndt PA (2007) An update on drug-induced immune haemolytic anemia. Immunohematology 23:105–119PubMed
5.
Zurück zum Zitat Garratty G, Arndt PA (2014) Drugs that have been shown to cause drug-induced immune hemolyticanemia or positive direct antiglobulin tests: some interesting findings since 2007. Immunohematology 30(2):66–79 PubMed Garratty G, Arndt PA (2014) Drugs that have been shown to cause drug-induced immune hemolyticanemia or positive direct antiglobulin tests: some interesting findings since 2007. Immunohematology 30(2):66–79 PubMed
6.
Zurück zum Zitat Yoshida K, Kurosaka D, Ozawa Y, Yokoyama T, Tajima N (2000) A case of rheumatoid arthritis associated with autoimmune hemolyticanemia due to weekly low-dose methotrexate therapy. Ryumachi 40(4):693–698PubMed Yoshida K, Kurosaka D, Ozawa Y, Yokoyama T, Tajima N (2000) A case of rheumatoid arthritis associated with autoimmune hemolyticanemia due to weekly low-dose methotrexate therapy. Ryumachi 40(4):693–698PubMed
7.
Zurück zum Zitat Woolley PV, Sacher RA, Priego VM, Schanfield MS, Bonnem EM (1983) Methotrexate-induced immune haemolytic anaemia. Br J Haematol 54(4):543–552CrossRefPubMed Woolley PV, Sacher RA, Priego VM, Schanfield MS, Bonnem EM (1983) Methotrexate-induced immune haemolytic anaemia. Br J Haematol 54(4):543–552CrossRefPubMed
8.
Zurück zum Zitat Arndt PA, Leger RM, Garratty G (1999) Serology of antibodies to second- and third-generation cephalosporin associated with immune hemolytic anemia and/or positive direct antiglobulin tests. Transfusion 39:1239–1246CrossRefPubMed Arndt PA, Leger RM, Garratty G (1999) Serology of antibodies to second- and third-generation cephalosporin associated with immune hemolytic anemia and/or positive direct antiglobulin tests. Transfusion 39:1239–1246CrossRefPubMed
9.
Zurück zum Zitat Johnson ST, Fueger JT, Gottschall JL (2007) One center’s experience: the serology and drugs associated with drug-induced immune hemolytic anemia—a new paradigm. Transfusion 47:697–702CrossRefPubMed Johnson ST, Fueger JT, Gottschall JL (2007) One center’s experience: the serology and drugs associated with drug-induced immune hemolytic anemia—a new paradigm. Transfusion 47:697–702CrossRefPubMed
10.
Zurück zum Zitat Petz LD (2004) A physician’s guide to transfusion in autoimmune haemolytic anaemia. Br J Haematol 124:712–716CrossRefPubMed Petz LD (2004) A physician’s guide to transfusion in autoimmune haemolytic anaemia. Br J Haematol 124:712–716CrossRefPubMed
11.
Zurück zum Zitat Chaplin H Jr (1990) Red cell-bound immunoglobulin as a predictor of severity of hemolysis in patients with autoimmune hemolytic anemia. Transfusion 30:576–578CrossRefPubMed Chaplin H Jr (1990) Red cell-bound immunoglobulin as a predictor of severity of hemolysis in patients with autoimmune hemolytic anemia. Transfusion 30:576–578CrossRefPubMed
12.
13.
Zurück zum Zitat Bercher ME (2005) The positive direct antiglobulin test and immune mediated red cell destruction. In: American Association of Blood Banks (ed) Technical manual, 15th edn. Bethesda, MA, AABB, pp 453–482 Bercher ME (2005) The positive direct antiglobulin test and immune mediated red cell destruction. In: American Association of Blood Banks (ed) Technical manual, 15th edn. Bethesda, MA, AABB, pp 453–482
14.
Zurück zum Zitat Das SS, Chaudhary R (2009) Utility of adsorption techniques in serological evaluation of warm autoimmune haemolytic anaemia. Blood Transfus 7:300–304PubMedPubMedCentral Das SS, Chaudhary R (2009) Utility of adsorption techniques in serological evaluation of warm autoimmune haemolytic anaemia. Blood Transfus 7:300–304PubMedPubMedCentral
15.
Zurück zum Zitat Garratty George (2010) Immune hemolytic anemia associated with drug therapy. Blood Rev 24:143–150CrossRefPubMed Garratty George (2010) Immune hemolytic anemia associated with drug therapy. Blood Rev 24:143–150CrossRefPubMed
16.
Zurück zum Zitat Daniels GL, Anstee DJ, Cartron JP et al (1995) Blood group terminology. From the ISBT working party on terminology for red cell surface antigens. Vox Sang 1995(69):265–279CrossRef Daniels GL, Anstee DJ, Cartron JP et al (1995) Blood group terminology. From the ISBT working party on terminology for red cell surface antigens. Vox Sang 1995(69):265–279CrossRef
17.
Zurück zum Zitat Daniels GL, Anstee DJ, Cartron JP et al (1996) Terminology for red cell surface antigens. Makuhari report. Vox Sang 71:246–248CrossRefPubMed Daniels GL, Anstee DJ, Cartron JP et al (1996) Terminology for red cell surface antigens. Makuhari report. Vox Sang 71:246–248CrossRefPubMed
18.
Zurück zum Zitat Montgomery W, NanceS Kavitsky D et al (1997) First example of hemolytic disease of the newborn (HDN) due to an antibody to a high incidence antigen present on multiple cell lines (MCL) (abstract). Transfusion 37(Suppl):41S Montgomery W, NanceS Kavitsky D et al (1997) First example of hemolytic disease of the newborn (HDN) due to an antibody to a high incidence antigen present on multiple cell lines (MCL) (abstract). Transfusion 37(Suppl):41S
19.
Zurück zum Zitat Jenner PW, Holland PV (1996) Diagnosis and management of transfusion reactions. In: Petz LD, Swisher SN, Kleinman S, Spence RK, Strauss RG (eds) Clinical practice of transfusion medicine, 3rd edn. Churchill-Livingstone, New York, pp 905–929 Jenner PW, Holland PV (1996) Diagnosis and management of transfusion reactions. In: Petz LD, Swisher SN, Kleinman S, Spence RK, Strauss RG (eds) Clinical practice of transfusion medicine, 3rd edn. Churchill-Livingstone, New York, pp 905–929
20.
Zurück zum Zitat Salama A, Berghofer H, Mueller-Eckhardt C (1992) Red blood cell transfusion in warm-type autoimmune haemolytic anaemia. Lancet 340:1515–1517CrossRefPubMed Salama A, Berghofer H, Mueller-Eckhardt C (1992) Red blood cell transfusion in warm-type autoimmune haemolytic anaemia. Lancet 340:1515–1517CrossRefPubMed
21.
Zurück zum Zitat Garratty G, Petz LD (1993) Transfusing patients with autoimmune haemolytic anaemia. Lancet 341:1220CrossRefPubMed Garratty G, Petz LD (1993) Transfusing patients with autoimmune haemolytic anaemia. Lancet 341:1220CrossRefPubMed
22.
Zurück zum Zitat Petz LD, Garratty G (2004) Blood transfusion in autoimmune hemolytic anemias. Immune hemolytic anemias, 2nd edn. Churchill Livingstone, New York, pp 375–400CrossRef Petz LD, Garratty G (2004) Blood transfusion in autoimmune hemolytic anemias. Immune hemolytic anemias, 2nd edn. Churchill Livingstone, New York, pp 375–400CrossRef
24.
Zurück zum Zitat Petz LD (2003) ‘Least incompatible’ units for transfusion in autoimmune hemolytic anemia: should we eliminate this meaningless term? a commentary for clinicians and transfusion medicine professionals. Transfusion 43:1503–1507CrossRefPubMed Petz LD (2003) ‘Least incompatible’ units for transfusion in autoimmune hemolytic anemia: should we eliminate this meaningless term? a commentary for clinicians and transfusion medicine professionals. Transfusion 43:1503–1507CrossRefPubMed
26.
Zurück zum Zitat Birkmeyer JD, Goodnough LT, AuBuchon JP, Noordsu PG, Littenberg B (1993) The cost effectiveness of preoperative autologous blood donation for total hip and knee replacement. Transfusion 33:544–551CrossRefPubMed Birkmeyer JD, Goodnough LT, AuBuchon JP, Noordsu PG, Littenberg B (1993) The cost effectiveness of preoperative autologous blood donation for total hip and knee replacement. Transfusion 33:544–551CrossRefPubMed
27.
Zurück zum Zitat Etchason J, Petz L, Keeler E, Calhoun L, Kleinman S, Snider C, Fink A, Brook R (1995) The cost effectiveness of preoperative autologous blood donations. N Engl J Med 332:719–724CrossRefPubMed Etchason J, Petz L, Keeler E, Calhoun L, Kleinman S, Snider C, Fink A, Brook R (1995) The cost effectiveness of preoperative autologous blood donations. N Engl J Med 332:719–724CrossRefPubMed
28.
Zurück zum Zitat Murray DJ (1999) Point of view: hemodilution as a method to reduce transfusion requirements in adolescent spine fusion surgery. Spine 24(3):223–224CrossRef Murray DJ (1999) Point of view: hemodilution as a method to reduce transfusion requirements in adolescent spine fusion surgery. Spine 24(3):223–224CrossRef
Metadaten
Titel
Autologous Blood Transfusion as a Life Saving Measure for a Trauma Patient with Fracture Femur and Drug Induced Hemolytic Anemia: A Case Report
verfasst von
Sumit Vishwakarma
Rahul Chaurasia
Arulselvi Subramanian
Vivek Trikha
Kabita Chatterjee
Publikationsdatum
25.08.2016
Verlag
Springer India
Erschienen in
Indian Journal of Hematology and Blood Transfusion / Ausgabe 2/2017
Print ISSN: 0971-4502
Elektronische ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-016-0715-6

Weitere Artikel der Ausgabe 2/2017

Indian Journal of Hematology and Blood Transfusion 2/2017 Zur Ausgabe

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

03.05.2024 Mammakarzinom Nachrichten

Wenn bei Mammakarzinomen durch eine neoadjuvante Chemotherapie ein Downstaging von nodal-positiv zu nodal-negativ gelingt, scheint es auch ohne Axilladissektion nur selten zu axillären Rezidiven zu kommen.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

02.05.2024 Prostatakarzinom Nachrichten

Eine adjuvante Radiotherapie nach radikaler Prostata-Op. bringt den Betroffenen wahrscheinlich keinen Vorteil. Im Gegenteil: Durch die Bestrahlung steigt offenbar das Risiko für Harn- und Stuhlinkontinenz.

ASS schützt nicht vor Brustkrebsrezidiven

02.05.2024 Mammakarzinom Nachrichten

Nützt nichts und ist vielleicht sogar schädlich: In einer Phase-3-Studie konnten täglich 300 mg ASS keine Brustkrebsrezidive bei Frauen vermeiden, die ein hohes Risiko für eine Tumorrückkehr aufwiesen. Tendenziell traten unter ASS sogar häufiger Rezidive auf als unter Placebo.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.